Senti Biosciences Inc (SNTI)

Currency in USD
1.6800
-0.0200(-1.18%)
Closed·
After Hours
1.6897+0.0097(+0.58%)
·
SNTI Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
SNTI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.62001.7300
52 wk Range
1.520116.9400
Key Statistics
Prev. Close
1.7
Open
1.73
Day's Range
1.62-1.73
52 wk Range
1.5201-16.94
Volume
69.93K
Average Volume (3m)
294.45K
1-Year Change
-22.22%
Book Value / Share
1.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SNTI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.5000
Upside
+703.57%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Senti Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Senti Biosciences Inc Company Profile

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Compare SNTI to Peers and Sector

Metrics to compare
SNTI
Peers
Sector
Relationship
P/E Ratio
−0.8x−2.4x−0.5x
PEG Ratio
−0.02−0.010.00
Price/Book
1.2x1.2x2.6x
Price / LTM Sales
-6.7x3.2x
Upside (Analyst Target)
-207.7%45.7%
Fair Value Upside
Unlock37.8%8.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.5000
(+703.57% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-1.41 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SNTI Income Statement

People Also Watch

131.10
ALAB
-4.12%
3.370
IMRX
-2.03%
16.380
QBTS
-4.71%
2.7400
SNGX
-6.48%
44.430
SMR
-11.51%

FAQ

What Stock Exchange Does Senti Biosciences Trade On?

Senti Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Senti Biosciences?

The stock symbol for Senti Biosciences is "SNTI."

What Is the Senti Biosciences Market Cap?

As of today, Senti Biosciences market cap is 43.80M.

What Is Senti Biosciences's Earnings Per Share (TTM)?

The Senti Biosciences EPS (TTM) is -9.62.

From a Technical Analysis Perspective, Is SNTI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Senti Biosciences Stock Split?

Senti Biosciences has split 1 times.

How Many Employees Does Senti Biosciences Have?

Senti Biosciences has 34 employees.

What is the current trading status of Senti Biosciences (SNTI)?

As of 02 Aug 2025, Senti Biosciences (SNTI) is trading at a price of 1.68, with a previous close of 1.70. The stock has fluctuated within a day range of 1.62 to 1.73, while its 52-week range spans from 1.52 to 16.94.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.